Precision Medicine In Segregating Endotypes in Preterm Birth

Precision Medicine In Segregating Endotypes in Preterm Birth

Michal Elovitz, MD, Director of the Prematurity Prevention Program at Penn Medicine, examines emerging concepts in prematurity prevention research at Penn, including the PROMISE trial, which is examining the use of 17 alpha hydroxyprogesterone caproate (17OHPC) in the prevention of preterm birth, and studies of the vaginal microbiome and cervical remodeling in prematurity.

 


Published

January 7, 2015

Created by

Penn Physician VideoLink